HC Wainwright & Co. Maintains Buy on Ensysce Biosciences, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju maintains a 'Buy' rating on Ensysce Biosciences (NASDAQ:ENSC) but has lowered the price target from $9 to $7.
September 25, 2023 | 10:12 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Ensysce Biosciences' price target has been lowered from $9 to $7 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target for Ensysce Biosciences by HC Wainwright & Co. could potentially lead to a short-term negative impact on the stock price. However, the maintained 'Buy' rating indicates continued confidence in the company's prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100